Pharmacists issue guidance for mass COVID-19 vaccination

By Samantha Black, PhD, ScienceBoard editor in chief

August 26, 2020 -- As society prepares for the rollout of COVID-19 vaccines, the American Society of Health-System Pharmacists (ASHP) has issued 10 guiding principles for development, distribution, allocation, and oversight of vaccines. The guidelines build on the organization's research and best practices expertise in pandemic preparedness, supply chain management, distribution, and clinical practice.

As the largest single vaccination effort the global community has ever undertaken, ASHP believes the following are vital to an effective vaccination rollout:

  • Enforce a transparent and rigorous process for vaccine development, approval, and postmarketing surveillance.
  • Collaborate and coordinate with U.S. and international public health partners to establish and implement a framework for the ethical and equitable global distribution of vaccines.
  • Engage, prepare, and protect the workforce of immunization personnel.
  • Expand patient access to COVID-19 vaccines by leveraging a highly qualified and empowered clinical pharmacy workforce in all settings of care.
  • Adhere to established best practices for proper storage and handling of vaccines throughout the supply chain from distribution to patient administration.
  • Ensure equitable allocation of COVID-19 vaccines across populations and communities, prioritized for greatest public health impact.
  • Achieve high acceptance and uptake of COVID-19 vaccines by minimizing vaccine hesitancy and misinformation.
  • Seek innovative solutions for adverse drug event monitoring and documentation to improve the thoroughness, accuracy, and usefulness of data collection for improved vaccine safety.
  • Ensure patient access to COVID-19 vaccines by preventing and removing financial barriers.
  • Remain vigilant with continued research and comprehensive surveillance procedures for COVID-19 vaccine use, safety, and effectiveness.
EpiVax licenses COVID-19 vaccine to EVT
EpiVax has licensed its COVID-19 vaccine candidate, EPV-CoV-19, to EpiVax Therapeutics (EVT), formerly known as EpiVax Oncology.
Data-sharing platform could help planning for future pandemics
In response to the global pandemic, the authors of a new paper are calling for a robust centralized platform to improve international data sharing among...
Moderna discusses supplying 80M doses of mRNA-1273 to EU
Moderna is in discussions with the European Commission to supply 80 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate,...
Novavax begins phase II trial of COVID-19 vaccine
Novavax has dosed the first participants in a phase II portion of an ongoing clinical trial to investigate the immunogenicity and safety of NVX-CoV2373,...
Catalent to support AstraZeneca COVID-19 vaccine manufacturing
Catalent and AstraZeneca have signed an agreement to expand manufacturing support for an adenovirus vector-based COVID-19 vaccine from the University...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter